SEP 30, 2015 1:30 PM PDT

Role of microRNA-mRNA interactions in Endometrioid Endometrial Carcinoma, a "Sample to Insight" biological exploration

Speaker
  • Principal Scientist, QIAGEN Bioinformatics
    Biography
      Jean-Noel Billaud, Ph.D. is Principal Scientist at QIAGEN Bioinformatics. He joined Ingenuity Systems (now QIAGEN) in 2008 as staff scientist for in silico research program in oncology and infectious diseases. Jean-Noel Billaud holds a Ph.D. in Blood Cell Biology from Paris VII, and has done his post-doctoral work at the Scripps Research Institute (San Diego, CA).

    Abstract

    Endometrial adenoarcinoma is a common cause of gynecological cancer death in Europe and North America. The most dominant subtype, Endometrioid Endometrial Cancer (EEC) accounts for >80% of this cancer and is estrogen-dependent. At diagnosis, 75% of women have the disease confined to the uterus which is considered Stage One. Five-year survival for Stage One patients is 80%, however, about 15–20% develop metastasis. EEC is generally associated with good prognosis, however the clinical course may be unpredictable as four different EEC subtypes have been recently defined. One “transcriptome” subtype has been identified and presents a worse prognosis. In this webinar, we will show how in silico solutions developed by QIAGEN Bioinformatics enabled us to analyze and identify the biological parameters involved in EEC tumor progression including signaling pathways, biological processes, and potential transcriptional drivers. Total RNA extracted from tissues obtained after surgical resection from three women at Stage One EEC was subjected to RNA-sequencing. The data was uploaded directly from the Sequence Read Archive and the FASTQ files were processed with Biomedical Genomics WorkBench for secondary analysis including mapping, quantification and differential expression analysis. Through streamlined integration analyzed data was seamlessly uploaded to Ingenuity Pathway Analysis (IPA) and Ingenuity Variant Analysis (IVA) for biological interpretation, providing a sample to insight solution.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 03, 2020 4:30 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    Loading Comments...
    Show Resources